Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amrovil is a brand of pheniramine maleate, a first-generation alkylamine antihistamine manufactured by Amros Pharmaceuticals. It functions as a competitive antagonist at the histamine H1 receptor, effectively blocking the physiological effects of histamine. It is primarily indicated for the treatment of various allergic conditions, including allergic rhinitis, urticaria, and hay fever. Due to its ability to cross the blood-brain barrier, it also possesses significant sedative properties and is sometimes used for the management of motion sickness and as a mild sedative. In the context of Amros Pharmaceuticals, it is provided as an injectable formulation for rapid relief of acute allergic symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pheniramine (Amros Pharmaceuticals).